JEMPERLI demonstrated efficacy across dMMR
recurrent or advanced
solid tumors1

Clinically meaningful responses achieved across patients with dMMR recurrent or advanced solid tumors1,2

GARNET Cohort A1+F overall response rate
GARNET Cohort A1-f duration of response
GARNET Cohort A1+F overall response rate
GARNET Cohort A1-f duration of response
  • Median follow-up for duration of response was 17.5 months measured from time of first response

The efficacy of JEMPERLI was investigated in a global, nonrandomized, multicenter, multiple cohort, open-label study of 209 patients with dMMR recurrent or advanced solid tumors who had progressed following systemic therapy and had no satisfactory alternative treatment options.* Patients received JEMPERLI 500 mg via intravenous infusion every 3 weeks for 4 doses, followed by 1000 mg every 6 weeks until disease progression or unacceptable toxicity.

CI=confidence interval; CR=complete response; dMMR=mismatch repair deficient; ORR=overall response rate; PR=partial response.

*Patients with dMMR endometrial cancer must have progressed on or after treatment with a platinum-containing regimen. Patients with dMMR colorectal cancer must have progressed after or been intolerant to a fluoropyrimidine, oxaliplatin, and irinotecan.1

Response to JEMPERLI was observed in a variety of dMMR tumor types1

  • Endometrial cancer (n=103)
  • Colorectal cancer (n=69)
  • Small intestinal cancer (n=12)
  • Gastric cancers (n=8)
  • Biliary neoplasm (n=2)
  • Liver cancer (n=2)
  • Ovarian cancer (n=2)
  • Adrenal cortical (n=1)
  • Breast cancer (n=1)
  • Genital neoplasm malignant female (n=1)
  • Pleural (n=1)
  • Unknown origin (n=1)

n values represent total population per tumor type included in the study, not number of responders.

Safety profile and tolerability of JEMPERLI were evaluated in patients with dMMR recurrent or advanced solid tumors (N=267)1


  • The most common adverse reaction (≥1%) leading to discontinuation was increased alanine aminotransferase (1.1%)
  • The most common adverse reactions (≥20%) were fatigue/asthenia, anemia, diarrhea, and nausea
  • Serious adverse reactions occurred in 34% of patients receiving JEMPERLI, including (>2% of patients) abdominal pain (3.7%), sepsis (2.6%), and acute kidney injury (2.2%)
  • Fatal adverse reaction due to respiratory failure occurred in 1 patient who received JEMPERLI

After initial 4 doses, 6-week dosing with JEMPERLI1

JEMPERLI offers a fixed-dose regimen every 6 weeks after the initial 4 doses, every 3 weeks.

Three weeks between Dose 4 and Dose 5.

Brochure icon

Find out more about another
  indication for JEMPERLI

Icon: JEMPERLI (dostarlimab-gxly) Mechanism of Action

Learn how JEMPERLI
activates T cells

Hand icon

Learn about support for
JEMPERLI at every step